P E

Presse Ethypharm

Press

at Ethypharm

Contact

Ethypharm Group

Ethypharm is a European pharmaceutical company focused on two areas: the Central Nervous System and Hospital injectables. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs 1,750 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible.

16/12/2021

Ethypharm is the first European pharmaceutical laboratory to be awarded the LUCIE 26000 label for its CSR commitment.

Saint-Cloud, France - December 16, 2021 - Ethypharm, a European pharmaceutical company specialising in the fields of the Central Nervous System and Injectable Hospital Drugs, announces that it has obtained the LUCIE 26000 label and joins Europe's leading committed and responsible community. A first for a pharmaceutical company. This certification initially concerns Ethypharm's main European subsidiaries: United Kingdom, France and Germany.  This certification reflects Ethypharm's commitment to a CSR approach that is fully integrated into its development and respects all its stakeholders.   A first in the Pharmaceutical Industry and at European level   Ethypharm is the first pharmaceutical laboratory to be awarded the LUCIE label. For the first time, the LUCIE Agency has extended the labelling process beyond France by including Ethypharm's two other European subsidiaries, Germany and the United Kingdom. The Group's other subsidiaries will enter the certification process at a later date.   "Through Ethypharm's certification, LUCIE is conquering Europe with the ambition of becoming the reference CSR certification agency by 2030. We are proud to take this next step, while contributing to Ethypharm's CSR commitment”. Said Saliha MARIET, Director of Operations of the LUCIE Agency.   Ethypharm's ambition: to improve the company's practices at all levels   With the LUCIE label, Ethypharm is committed to strengthening its social and environmental actions with the following objectives: to act on its core business, to involve its employees more and more concretely, to strengthen the dialogue with its external stakeholders and to make its CSR impact more visible in all its actions.   This deep commitment is aligned with 7 themes:   • Governance of the organisation • Human rights • Labour relations and working conditions • Environmental issues • Good business practice • Patient/user issues  • Communities and local development   "This cross-disciplinary project was supported by a multidisciplinary team. It is fully in line with Ethypharm's development strategy in Europe and internationally. We have placed corporate social responsibility at the heart of our governance. With the LUCIE label, we seek to inspire and encourage Ethypharm's teams to go even further in their environmental, human and social commitments. Obtaining the label from an independent body is part of our desire to build a solid and sustainable company to provide innovative and appropriate solutions to patients", said Daniela Schulte, Chief Human Resources & CSR Officer.     An external audit was carried out by the independent certification body Bureau Veritas Certification and then, after examining the report and the commitments made by Ethypharm to progress over the next three years, an independent labelling committee awarded the LUCIE label.     CSR commitment at the heart of Ethypharm's activities:   - A more impactful and collaborative approach close to Ethypharm's teams. Local teams are mobilised to strengthen and enhance their local roots through local initiatives.    - A more responsible approach with, in particular, a sustainable commitment to the Group's responsible purchasing, to reducing our greenhouse gas emissions and to taking account of inclusion in talent management.    - A more visible approach by communicating our mission, progress and results to all our stakeholders.    About Ethypharm   Ethypharm is a European pharmaceutical company focused on two areas: the Central Nervous System and Hospital injectables. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of, and access to,  its medicines by as many people as possible. For more information about Ethypharm, visit www.ethypharm.com and follow us on LinkedIn. Media contact  Avril PONNELLE - Group Communication Manager - +33 1 4112 1720 - presse@ethypharm.com     About the LUCIE Agency Created in 2007, the LUCIE 26000 label rewards an organisation's commitment to social responsibility according to the guidelines of the ISO 26000 standard. The LUCIE Agency is also developing various solutions to enable all organisations to become more committed and responsible through thematic labels such as ENVOL, the Responsible Digital label or Biodiversity Progress. The LUCIE Community now brings together more than 950 organisations that share the same values and the same desire: to make the world fairer and more respectful of people and territories. Our mission: to give organisations the means to become actors with a positive impact.

Read more

02/12/2021

Ethypharm has obtained marketing authorisations for the first Immediate Release orodispersible tablets of morphine in Germany, France and the United Kingdom.

Saint-Cloud, France – December 2nd, 2021 – Ethypharm has successfully used a European decentralized procedure to obtain its marketing authorisations (MA) for the 1st Immediate-Release orodispersible tablets of morphine in a broad range of dosages. This full in-house development will help Ethypharm to respond to some patients’ specific needs in the field of pain in the three largest European morphine markets: Germany, France and the United Kingdom. The Central Nervous System (CNS) is one of Ethypharm’s two areas of focus. In its commitment to help manage severe pain, the company is already offering several analgesics, including Immediate-Release and Sustained-Release morphine products.  Having a choice of dosages and forms is critical for prescribers to customise pain treatments according to their patients’ needs. In that regard, certain populations have special needs that might currently not be fully met. For example, both the elderly and the children population would need lower dosages than currently exists in the market in an oral solid dose form; these two populations groups may also have swallowing difficulties.  “We are proud of this successful development of the first Immediate-Release orodispersible tablet of morphine”, explains Marianne Henrion, Group R&D Director at Ethypharm. “Our newly approved product offers a broad range of dosages, introducing the lowest strengths of oral solid dose morphine in the European market (1mg and 2.5mg).”   “This Marketing Authorisation confirms our ability to answer patients’ needs” concludes Jean Monin, Chief Commercial Operations Officer at Ethypharm. “Our product is adapted for all patients, from children over 6-months-old to the elderly. Expected in the first half of 2022, this will be our first product launch by our own affiliates on a European scale.”   About Ethypharm Ethypharm is a European pharmaceutical company focused on two areas: the Central Nervous System and Hospital Injectables. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs circa 1,750 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of, and access to, its medicines, by as many people as possible. For more information, visit www.ethypharm.com and follow us on LinkedIn Media Relations Mai Tran, presse@ethypharm.com, + 33 (0) 6 64 74 70 80

Read more

14/10/2021

Ethypharm consolidates its European presence with the integration of Altan, now led by Manuel Casegas as its General Manager

Saint-Cloud, France – October 14th, 2021 – Ethypharm is pleased to announce that it has successfully completed the acquisition of Altan and has now welcomed into the group all of its employees. Led by Manuel Casegas, this new affiliate gives Ethypharm a direct presence in Spain and expands its hospital injectables portfolio and R&D pipeline.  Ethypharm continues its ambitious growth strategy and consolidates its direct presence in Europe. With the integration of Altan, Ethypharm establishes itself in the fifth-largest pharmaceutical market in Europe and the eighth-largest market worldwide in terms of revenue. Ethypharm also benefits from an enlarged portfolio of high-quality hospital injectable products and a rich pipeline of R&D projects, which perfectly fit in the focus of the company.  To lead its new affiliate in Spain, Ethypharm has appointed Manuel Casegas as General Manager. “Given his role as Chief Industrial Officer of Altan over the past 3 years, Manuel Casegas knows very well Altan, its products and its teams. Ethypharm and Altan are highly complementary. In making this choice, we wanted to ensure business continuity. We trust that under Manuel’s leadership, Altan’s business will continue to grow and thrive, with an ambition higher than ever before.” comments Jean Monin, Chief Commercial Operations Officer of Ethypharm. Manuel Casegas graduated as a pharmacist from the University of Burgundy in France. After close to 20 years at Roche and Famar, he took over the responsibility of the industrial operations of Altan three years ago. “Integrating Ethypharm is a major milestone for Altan” said Manuel Casegas. “As Ethypharm’s General Manager in Spain, my first priority will be to ensure a rapid and smooth integration of Altan into Ethypharm so as to make the most of our combined strengths to serve health and patients.”  With this acquisition Ethypharm now has a full presence in the top 5 European markets and net sales of close to 400M€ (2020). About Ethypharm Ethypharm is a European pharmaceutical company focused on two areas: the Central Nervous System and Hospital injectables. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs 1,750 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information, visit www.ethypharm.com and follow us on LinkedIn Media Relations Mai Tran, presse@ethypharm.com, + 33 (0) 6 64 74 70 80 IQVIA, Top 10 Pharmaceutical Markets Worldwide, 2020

Read more

25/08/2021

Prescriptions of medical cannabis dried flowers have started for patients included in the French pilot programme

St-Cloud, France, 25th August 2021 – The prescriptions of cannabis flowers to patients have started in France. The first batches provided by Aurora and distributed by Ethypharm are now available to the healthcare professionals of the first-ever French pilot program. Early 2021, Ethypharm and Aurora Europe announced their selection by the National Agency for the Safety of Medicines and Health Products (ANSM) as sole primary suppliers in the categories of medical cannabis dried flowers. Under the terms of the exclusive partnership, Aurora supplies the products and Ethypharm’s French subsidiary, Laboratoires Ethypharm, is responsible for pharmaceutical distribution. In a decree dated 7 October 2020, French authorities set the framework for a two-year pilot program of medical cannabis in France, which started earlier in 2021. Ethypharm and Aurora Europe were amongst the six producer-and-distributor tandems selected to provide medical cannabis products. They were nominated as the primary supplier for all the three lots they applied for (out of nine awarded) which are: Aurora 20/1 XPE (high-THC dried flowers), Aurora 8/8 XPE (THC: CBD balanced dried flowers) and Aurora 1/12 XPE (high-CBD dried flowers). Dried flowers are to be administrated with a vaporizer by STORZ & BICKEL, a well-known product tested and used by patients across Europe, recently selected by the ANSM. This solution was particularly expected to complement the other medical cannabis forms already made available in the pilot. With that solution in place, the Ethypharm-Aurora tandem is now able to provide the entire supply of medical cannabis dried flowers to French patients during the pilot program. Collaboration and partnerships are indeed part of Ethypharm’s DNA. By looking for the optimal partner in any country or region of the world, Ethypharm develops new ways to provide patients with the medical treatment they need. “Combining our pharmaceutical skills is, in our view, the right approach to build trust and confidence in medical cannabis for the long term in France. We want to be a driving force to support patients suffering from chronic pain when there is no other therapeutic option than medical cannabis. We are building the same type of cooperation in Germany with our partner Clever Leaves” declared Jean Monin, Chief Commercial Operations Officer of Ethypharm. “With its deep expertise in Central Nervous System disorders and experience in highly regulated medicines, Ethypharm is well prepared to collaborate with health authorities and physicians. If the pilot is positive, Ethypharm will, as a pharmaceutical company, secure distribution and access for the patient to the new option of therapeutic cannabis.“ The first batches of the three types of pharmaceutical quality pharmaceutical-grade medical cannabis dried flowers (THC dominant, balanced and CBD dominant) were delivered a few weeks ago to the French authorities. Aurora Nordic, production facility in Odense, Denmark Aurora’s European Good Manufacturing Practices EU-GMP certified by Danish Health Authorities, is committed to providing sufficient and consistent supply to patients and healthcare professionals as part of the pilot program. Up to 3,000 patients will benefit from the two-year trial led by ANSM. “Aurora’s participation in the French pilot program is a significant step toward providing better access to patients and will support the destigmatization of medical cannabis in France,” says Dr. Axel Gille, President of Aurora Europe. “Aurora has a proven track record of supporting the advancement of international medical cannabis markets alongside government bodies and with a deep commitment to compliance and excellence in the large-scale production of high-quality pharmaceutical grade medical cannabis. If successful, this pilot program could lead to one of the largest regulated markets for medical cannabis in Europe.” About Aurora Europe Aurora Europe, headquartered in Berlin, Germany, is a subsidiary of Aurora Cannabis Inc., a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives. Aurora Europe supplies pharmaceutical quality medical cannabis products to patients throughout Europe. In 2015, Aurora entered the market in Europe and today operates as one of the largest authorised producers and distributors of medical cannabis in Europe. Aurora’s internal network of EU GMP facilities continues to bring pharmaceutical quality, premium medical cannabis to patients worldwide, at the forefront in Europe with its facility Aurora Nordic in Odense, Denmark. For more information visit www.auroramedicine.com and follow us on LinkedIn. About Ethypharm Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information, visit www.ethypharm.com and follow us on LinkedIn. Media Relations Mai Tran, presse@ethypharm.com, + 33 (0) 6 64 74 70 80

Read more

Ethypharm Group

Ethypharm is a European pharmaceutical company focused on two areas: the Central Nervous System and Hospital injectables. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs 1,750 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible.

Presse Ethypharm

Press

Contact
16/12/2021

Ethypharm is the first European pharmaceutical laboratory to be awarded the LUCIE 26000 label for its CSR commitment.

Saint-Cloud, France - December 16, 2021 - Ethypharm, a European pharmaceutical company specialising in the fields of the Central Nervous System and Injectable Hospital Drugs, announces that it has obtained the LUCIE 26000 label and joins Europe's leading committed and responsible community. A first for a pharmaceutical company. This certification initially concerns Ethypharm's main European subsidiaries: United Kingdom, France and Germany.  This certification reflects Ethypharm's commitment to a CSR approach that is fully integrated into its development and respects all its stakeholders.   A first in the Pharmaceutical Industry and at European level   Ethypharm is the first pharmaceutical laboratory to be awarded the LUCIE label. For the first time, the LUCIE Agency has extended the labelling process beyond France by including Ethypharm's two other European subsidiaries, Germany and the United Kingdom. The Group's other subsidiaries will enter the certification process at a later date.   "Through Ethypharm's certification, LUCIE is conquering Europe with the ambition of becoming the reference CSR certification agency by 2030. We are proud to take this next step, while contributing to Ethypharm's CSR commitment”. Said Saliha MARIET, Director of Operations of the LUCIE Agency.   Ethypharm's ambition: to improve the company's practices at all levels   With the LUCIE label, Ethypharm is committed to strengthening its social and environmental actions with the following objectives: to act on its core business, to involve its employees more and more concretely, to strengthen the dialogue with its external stakeholders and to make its CSR impact more visible in all its actions.   This deep commitment is aligned with 7 themes:   • Governance of the organisation • Human rights • Labour relations and working conditions • Environmental issues • Good business practice • Patient/user issues  • Communities and local development   "This cross-disciplinary project was supported by a multidisciplinary team. It is fully in line with Ethypharm's development strategy in Europe and internationally. We have placed corporate social responsibility at the heart of our governance. With the LUCIE label, we seek to inspire and encourage Ethypharm's teams to go even further in their environmental, human and social commitments. Obtaining the label from an independent body is part of our desire to build a solid and sustainable company to provide innovative and appropriate solutions to patients", said Daniela Schulte, Chief Human Resources & CSR Officer.     An external audit was carried out by the independent certification body Bureau Veritas Certification and then, after examining the report and the commitments made by Ethypharm to progress over the next three years, an independent labelling committee awarded the LUCIE label.     CSR commitment at the heart of Ethypharm's activities:   - A more impactful and collaborative approach close to Ethypharm's teams. Local teams are mobilised to strengthen and enhance their local roots through local initiatives.    - A more responsible approach with, in particular, a sustainable commitment to the Group's responsible purchasing, to reducing our greenhouse gas emissions and to taking account of inclusion in talent management.    - A more visible approach by communicating our mission, progress and results to all our stakeholders.    About Ethypharm   Ethypharm is a European pharmaceutical company focused on two areas: the Central Nervous System and Hospital injectables. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of, and access to,  its medicines by as many people as possible. For more information about Ethypharm, visit www.ethypharm.com and follow us on LinkedIn. Media contact  Avril PONNELLE - Group Communication Manager - +33 1 4112 1720 - presse@ethypharm.com     About the LUCIE Agency Created in 2007, the LUCIE 26000 label rewards an organisation's commitment to social responsibility according to the guidelines of the ISO 26000 standard. The LUCIE Agency is also developing various solutions to enable all organisations to become more committed and responsible through thematic labels such as ENVOL, the Responsible Digital label or Biodiversity Progress. The LUCIE Community now brings together more than 950 organisations that share the same values and the same desire: to make the world fairer and more respectful of people and territories. Our mission: to give organisations the means to become actors with a positive impact.

02/12/2021

Ethypharm has obtained marketing authorisations for the first Immediate Release orodispersible tablets of morphine in Germany, France and the United Kingdom.

Saint-Cloud, France – December 2nd, 2021 – Ethypharm has successfully used a European decentralized procedure to obtain its marketing authorisations (MA) for the 1st Immediate-Release orodispersible tablets of morphine in a broad range of dosages. This full in-house development will help Ethypharm to respond to some patients’ specific needs in the field of pain in the three largest European morphine markets: Germany, France and the United Kingdom. The Central Nervous System (CNS) is one of Ethypharm’s two areas of focus. In its commitment to help manage severe pain, the company is already offering several analgesics, including Immediate-Release and Sustained-Release morphine products.  Having a choice of dosages and forms is critical for prescribers to customise pain treatments according to their patients’ needs. In that regard, certain populations have special needs that might currently not be fully met. For example, both the elderly and the children population would need lower dosages than currently exists in the market in an oral solid dose form; these two populations groups may also have swallowing difficulties.  “We are proud of this successful development of the first Immediate-Release orodispersible tablet of morphine”, explains Marianne Henrion, Group R&D Director at Ethypharm. “Our newly approved product offers a broad range of dosages, introducing the lowest strengths of oral solid dose morphine in the European market (1mg and 2.5mg).”   “This Marketing Authorisation confirms our ability to answer patients’ needs” concludes Jean Monin, Chief Commercial Operations Officer at Ethypharm. “Our product is adapted for all patients, from children over 6-months-old to the elderly. Expected in the first half of 2022, this will be our first product launch by our own affiliates on a European scale.”   About Ethypharm Ethypharm is a European pharmaceutical company focused on two areas: the Central Nervous System and Hospital Injectables. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs circa 1,750 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of, and access to, its medicines, by as many people as possible. For more information, visit www.ethypharm.com and follow us on LinkedIn Media Relations Mai Tran, presse@ethypharm.com, + 33 (0) 6 64 74 70 80

14/10/2021

Ethypharm consolidates its European presence with the integration of Altan, now led by Manuel Casegas as its General Manager

Saint-Cloud, France – October 14th, 2021 – Ethypharm is pleased to announce that it has successfully completed the acquisition of Altan and has now welcomed into the group all of its employees. Led by Manuel Casegas, this new affiliate gives Ethypharm a direct presence in Spain and expands its hospital injectables portfolio and R&D pipeline.  Ethypharm continues its ambitious growth strategy and consolidates its direct presence in Europe. With the integration of Altan, Ethypharm establishes itself in the fifth-largest pharmaceutical market in Europe and the eighth-largest market worldwide in terms of revenue. Ethypharm also benefits from an enlarged portfolio of high-quality hospital injectable products and a rich pipeline of R&D projects, which perfectly fit in the focus of the company.  To lead its new affiliate in Spain, Ethypharm has appointed Manuel Casegas as General Manager. “Given his role as Chief Industrial Officer of Altan over the past 3 years, Manuel Casegas knows very well Altan, its products and its teams. Ethypharm and Altan are highly complementary. In making this choice, we wanted to ensure business continuity. We trust that under Manuel’s leadership, Altan’s business will continue to grow and thrive, with an ambition higher than ever before.” comments Jean Monin, Chief Commercial Operations Officer of Ethypharm. Manuel Casegas graduated as a pharmacist from the University of Burgundy in France. After close to 20 years at Roche and Famar, he took over the responsibility of the industrial operations of Altan three years ago. “Integrating Ethypharm is a major milestone for Altan” said Manuel Casegas. “As Ethypharm’s General Manager in Spain, my first priority will be to ensure a rapid and smooth integration of Altan into Ethypharm so as to make the most of our combined strengths to serve health and patients.”  With this acquisition Ethypharm now has a full presence in the top 5 European markets and net sales of close to 400M€ (2020). About Ethypharm Ethypharm is a European pharmaceutical company focused on two areas: the Central Nervous System and Hospital injectables. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs 1,750 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information, visit www.ethypharm.com and follow us on LinkedIn Media Relations Mai Tran, presse@ethypharm.com, + 33 (0) 6 64 74 70 80 IQVIA, Top 10 Pharmaceutical Markets Worldwide, 2020

25/08/2021

Prescriptions of medical cannabis dried flowers have started for patients included in the French pilot programme

St-Cloud, France, 25th August 2021 – The prescriptions of cannabis flowers to patients have started in France. The first batches provided by Aurora and distributed by Ethypharm are now available to the healthcare professionals of the first-ever French pilot program. Early 2021, Ethypharm and Aurora Europe announced their selection by the National Agency for the Safety of Medicines and Health Products (ANSM) as sole primary suppliers in the categories of medical cannabis dried flowers. Under the terms of the exclusive partnership, Aurora supplies the products and Ethypharm’s French subsidiary, Laboratoires Ethypharm, is responsible for pharmaceutical distribution. In a decree dated 7 October 2020, French authorities set the framework for a two-year pilot program of medical cannabis in France, which started earlier in 2021. Ethypharm and Aurora Europe were amongst the six producer-and-distributor tandems selected to provide medical cannabis products. They were nominated as the primary supplier for all the three lots they applied for (out of nine awarded) which are: Aurora 20/1 XPE (high-THC dried flowers), Aurora 8/8 XPE (THC: CBD balanced dried flowers) and Aurora 1/12 XPE (high-CBD dried flowers). Dried flowers are to be administrated with a vaporizer by STORZ & BICKEL, a well-known product tested and used by patients across Europe, recently selected by the ANSM. This solution was particularly expected to complement the other medical cannabis forms already made available in the pilot. With that solution in place, the Ethypharm-Aurora tandem is now able to provide the entire supply of medical cannabis dried flowers to French patients during the pilot program. Collaboration and partnerships are indeed part of Ethypharm’s DNA. By looking for the optimal partner in any country or region of the world, Ethypharm develops new ways to provide patients with the medical treatment they need. “Combining our pharmaceutical skills is, in our view, the right approach to build trust and confidence in medical cannabis for the long term in France. We want to be a driving force to support patients suffering from chronic pain when there is no other therapeutic option than medical cannabis. We are building the same type of cooperation in Germany with our partner Clever Leaves” declared Jean Monin, Chief Commercial Operations Officer of Ethypharm. “With its deep expertise in Central Nervous System disorders and experience in highly regulated medicines, Ethypharm is well prepared to collaborate with health authorities and physicians. If the pilot is positive, Ethypharm will, as a pharmaceutical company, secure distribution and access for the patient to the new option of therapeutic cannabis.“ The first batches of the three types of pharmaceutical quality pharmaceutical-grade medical cannabis dried flowers (THC dominant, balanced and CBD dominant) were delivered a few weeks ago to the French authorities. Aurora Nordic, production facility in Odense, Denmark Aurora’s European Good Manufacturing Practices EU-GMP certified by Danish Health Authorities, is committed to providing sufficient and consistent supply to patients and healthcare professionals as part of the pilot program. Up to 3,000 patients will benefit from the two-year trial led by ANSM. “Aurora’s participation in the French pilot program is a significant step toward providing better access to patients and will support the destigmatization of medical cannabis in France,” says Dr. Axel Gille, President of Aurora Europe. “Aurora has a proven track record of supporting the advancement of international medical cannabis markets alongside government bodies and with a deep commitment to compliance and excellence in the large-scale production of high-quality pharmaceutical grade medical cannabis. If successful, this pilot program could lead to one of the largest regulated markets for medical cannabis in Europe.” About Aurora Europe Aurora Europe, headquartered in Berlin, Germany, is a subsidiary of Aurora Cannabis Inc., a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives. Aurora Europe supplies pharmaceutical quality medical cannabis products to patients throughout Europe. In 2015, Aurora entered the market in Europe and today operates as one of the largest authorised producers and distributors of medical cannabis in Europe. Aurora’s internal network of EU GMP facilities continues to bring pharmaceutical quality, premium medical cannabis to patients worldwide, at the forefront in Europe with its facility Aurora Nordic in Odense, Denmark. For more information visit www.auroramedicine.com and follow us on LinkedIn. About Ethypharm Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information, visit www.ethypharm.com and follow us on LinkedIn. Media Relations Mai Tran, presse@ethypharm.com, + 33 (0) 6 64 74 70 80

18/06/2021

Ethypharm to acquire Altan Pharma, entering the Spanish market and enhancing its Critical Care portfolio and R&D pipeline

Saint-Cloud, France – June 18th, 2021 – Ethypharm announces today that it has entered into a definitive agreement to acquire Altan Pharma, a specialty pharmaceutical company that develops, manufactures and markets injectable medicines for hospital use. Thanks to the strong presence of Altan Pharma in Spain, Ethypharm will reach full commercial coverage of the top 5 European markets upon closing, which is expected in the second half of 2021. Ethypharm will also benefit from an enlarged portfolio of high quality hospital injectable products and a rich pipeline of R&D projects, which fit perfectly with its existing Critical Care franchise.   “Altan Pharma’s product portfolio and geographic coverage are highly complementary to those of Ethypharm. We look forward to welcoming Altan Pharma’s teams, as we are convinced that together, our product portfolio, our R&D and our industrial expertise, will put us in a stronger position to fulfil our commitment to the patients we serve”, said Bertrand Deluard, CEO of Ethypharm. “The Altan Pharma acquisition is an important milestone in Ethypharm’s transformation journey. By entering the Spanish market and reinforcing our Critical Care franchise, Ethypharm proves once again its ability to execute on its long-term growth ambition.”  “Joining an established European specialty pharmaceutical company, with a strong direct commercial presence in Europe beyond Spain and in major growth territories for injectable medicines, will be a booster for the international expansion of Altan Pharma’s product portfolio”  said Guillermo Herrera, CEO of Altan Pharma. “Since its inception in 1998, Altan Pharma has been committed to improving patient care by providing specialty medications of superior quality and value for the benefit of patients and caregivers.” Jefferies International Limited acted as sole financial adviser to Altan Pharma on the transaction. About Altan Pharma Altan Pharma is a specialty pharmaceutical company that develops, manufactures and markets injectable medications for the hospital and other provider segments. Altan is a premier, global injectable drug company that is committed to improving patient care by providing specialty medications of superior quality and value for the benefit of patients and caregivers. Altan Pharma currently markets a portfolio of over 40 injectable medications used in pain and anaesthesia, epilepsy, oncology, anti-infectives, cardiovascular, and gynecology and is developing an attractive portfolio of additional products in these areas. Altan Pharma realised almost half of its 2020 sales through its own commercial operations in Spain, with the other half coming from the successful development of an international network of distributors and partners in more than 40 countries. Altan Pharma owns and operates two EU GMP manufacturing sites in Spain, located in Bernedo and Casarubios, which offer a wide range of injectable forms, including flexible plastic bags, liquid vials, lyophilized vials and ampoules. Circa 250 employees in R&D, manufacturing, market access, commercial and support functions make up the highly committed workforce of Altan Pharma. For more information, visit www.altanpharma.eu   About Ethypharm Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information, visit www.ethypharm.com and follow us on LinkedIn   Media Relations Mai Tran, presse@ethypharm.com, + 33 (0) 6 64 74 70 80

19/05/2021

Ethypharm reinforces its late-stage R&D pipeline with a novel acute treatment of migraine

Saint-Cloud, France – May 19th, 2021 – Ethypharm announces today that it has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. Migraine is one of the most common neurological conditions, affecting about 12% of the population in Europe. In the management of acute migraine attacks, many medicines are already available. However, patients may not be always satisfied with the efficacy of existing treatments and some may have concerns about their potential side effects. There is therefore a need to offer further alternatives to patients suffering from acute migraine attacks. With this in mind, Dr Reddy’s developed for the US market a new oral liquid formulation of the nonsteroidal anti-inflammatory drug celecoxib and conducted pivotal studies which supported the US FDA approval of their product in May 2020. This agreement is strategic for both parties. Through its focus on pain, Ethypharm had for a long time identified the need to offer patients new treatment options for acute migraine. On Dr Reddy’s side, it was important to give access to European patients to this latest product emerging from its proprietary portfolio of acute migraine treatments. “Ethypharm has the right expertise, experience and presence in Europe; this is why we concluded the outlicensing of the development, registration and commercialization rights of our celecoxib oral solution for the UK + EU4 markets (Germany, Italy, France and Spain) to Ethypharm” said G B Ramesh Murthy, VP Business Development, Proprietary Products at Dr Reddy’s. A few development steps remain before being able to file this product in Europe. The product therefore enters Ethypharm’s late-stage development pipeline. With a European market for migraine medicines estimated at 550M€ in 2019, Ethypharm aims to rapidly obtain the necessary Marketing Authorisations to be able to launch this novel treatment in the United Kingdom, Germany, France, Italy and Spain. “Ethypharm is committed to improve the lives of patients who suffer from debilitating Central Nervous System conditions. Celecoxib in this innovative formulation will be a new alternative for UK and EU4 patients who suffer from acute migraine attacks.” said Frédéric Molin, EVP Corporate Development of Ethypharm. He also added: “If we look beyond this agreement, Ethypharm offers a strong platform to non-European companies wishing to maximise the potential of their products which fall in our areas of expertise. We are truly open to external innovations and actively looking to engage in discussions with further partners. ” About Ethypharm Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information visit www.ethypharm.com and follow us on LinkedIn Corporate Media Relations Contact Mai Tran, presse@ethypharm.com, + 33 (0) 6 64 74 70 80

06/05/2021

Hélène Moore appointed Head of Ethypharm Digital Therapy with responsibility for building a European Leader in this innovative field.

One month after the acquisition of the exclusive rights for two innovative digital therapies in the Central Nervous System, deprexis® and vorvida® , Ethypharm announces the establishment of a new business unit, Ethypharm Digital Therapy SAS, and the appointment of Hélène Moore as Executive Vice-President (EVP) and Head of the entity. Focused in the areas of Central Nervous System (CNS) and Critical care, Ethypharm has taken a major strategic step with the addition of clinical digital therapies to its group portfolio. Bertrand Deluard, CEO of Ethypharm said “Digital therapies have reached clinical relevance. Meanwhile, COVID-19 pandemic has accelerated the digitization of healthcare and patients’ lives. It is opening the door to a better acceptance and dissemination of digital therapies. Ethypharm always strives to provide the best therapeutic solutions to patients and their physicians. The partnership with GAIA, a pioneer in digital health, is our first step to provide access to these disruptive innovations. We now have to be efficient and to ensure access to people in need in a timely manner.” The dedicated new entity, Ethypharm Digital Therapy SAS (EDT), has been set up in order to achieve these objectives. EDT will quickly grow and bring together "digital therapy-specific expertise” in medical affairs, market access, digital medical devices, as well as an understanding of DTx marketing and technologies. The entity will receive support from the rest of the group, in research and development for example. The team will develop the clinical acceptance of the innovative approach to digital therapies, the understanding and adoption by health authorities, prescribers, and patients. Entrepreneurship, experience in business life sciences, ambition and energy are needed to realise EDT’s ambition of becoming a European leader in CNS digital therapies. Ethypharm has appointed Hélène Moore as head of its new entity (EDT). As an experienced executive of both large and small life science companies combined with an entrepreneurial spirit and a well-rounded commercial and corporate development skills, Hélène Moore, EVP and Head of Ethypharm Digital Therapy SAS has accepted the challenge. “I am delighted and humbled to lead this new Ethypharm endeavour and looking forward to surrounding myself with talented people who will make EDT a success story for Ethypharm. With digital therapies, we are clearly in the future of healthcare and I strongly believe in the relevance of these innovations.” she said. Depression will be the first focus. Several years ago, the European commission identified depression and depression-related problems among the most pressing public health concerns. They account for more than 7% of all estimated ill health and premature mortality in Europe. deprexis® is an online digital therapy using cognitive behavioural therapy-based techniques for patients suffering from mild to severe depression or depressive symptoms. deprexis® has been subjected to 12 randomized controlled trials gathering almost 2,900 patients with depressive symptoms or depressive disorders (i.e. major depressive disorder, dysthymia). The solution obtained reimbursement from health authorities in Germany few months ago. The global Digital Therapeutics market size is expected to be worth US$ 29.1 billion by 2030, according to a report by Vision Research Reports released few days ago. About Ethypharm Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information visit www.ethypharm.com and follow us on LinkedIn Media Contacts Ethypharm: Mai Tran, presse@ethypharm.com, + 33 (0)6 64 74 70 80